347 related articles for article (PubMed ID: 31880861)
1. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
6. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
8. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
[TBL] [Abstract][Full Text] [Related]
12. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
13. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
14. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
[TBL] [Abstract][Full Text] [Related]
15. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
16. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
[TBL] [Abstract][Full Text] [Related]
17. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F; Russano M; Berruti A; Mansueto G; Migliorino MR; Adamo V; Aprile G; Gelibter A; Ficorella C; Falcone A; Russo A; Aieta M; Maio M; Martelli O; Barni S; Napolitano A; Roca E; Quadrini S; Iacono D; Russo A; Calvetti L; Occhipinti MA; Cortellini A; Vasile E; Passiglia F; Imperatori M; Calabrò L; Di Giacomo AM; Petrelli F; Pasquini G; Franchina T; Venditti O; Intagliata S; Galvano A; Fioroni I; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Mar; 20(3):319-326. PubMed ID: 32011207
[No Abstract] [Full Text] [Related]
18. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A
Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415
[No Abstract] [Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.
Ravanelli M; Agazzi GM; Milanese G; Roca E; Silva M; Tiseo M; Rondi P; Baggi A; Ganeshan B; Muri M; Panni S; Botti C; Sverzellati N; Maroldi R; Berruti A; Farina D
Eur J Radiol; 2019 Sep; 118():251-256. PubMed ID: 31439251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]